A Noncanonical MET Exon 14 Splice‐Site Variant in Pulmonary Sarcomatoid Carcinoma With Response to Capmatinib
Thoracic Cancer · 2026-08 · 17 (15)
DOI: 10.1111/1759-7714.70371 ↗Kurz gefasst
Fallbericht in der Zeitschrift Thoracic Cancer, online erschienen am 07.08.2026. Verfasst von Hyung-Joo Oh und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonology, Department of Internal Medicine, Chonnam National University Medical School, Gwangju, South Korea. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-met, Lung Neoplasms, Benzamides, Triazines. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
MET exon 14 skipping is an actionable oncogenic driver in non–small cell lung carcinoma (NSCLC); however, noncanonical splice‐region variants are frequently classified as variants of unknown significance (VUS), which may result in missed therapeutic opportunities and highlight limitations in current DNA next‐generation sequencing (NGS) reporting criteria. We report a patient with pulmonary sarcomatoid carcinoma harboring a noncanonical MET splice donor–proximal indel (c.3022_3028 + 13delinsA), initially interpreted as a VUS, who achieved a rapid and durable response to capmatinib. Subsequent RNA sequencing and droplet digital PCR (ddPCR) confirmed MET exon 14 skipping, supporting the value of orthogonal transcript‐level validation for exon‐adjacent variants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pulmonology, Department of Internal Medicine, Chonnam National University Medical School, Gwangju, South Korea.
- Lung Cancer Center, Chonnam National University Hwasun Hospital, Gwangju, South Korea.
- Department of Pathology, Chonnam National University Medical School, Gwangju, South Korea.
- Department of Pathology & Translational Genomics, Samsung Medical Center, Sungkyungwan University School of Medicine, Seoul, South Korea.
ORCID-Profile: Hyung-Joo Oh, Yoon-La Choi, Jung-Hwan Lim, Cheol-Kyu Park, In-Jae Oh, Young-Chul Kim
Zitieren
APA
Oh, H. J., Choi, Y. D., Choi, Y. L., Park, H. Y., Yoon, J. Y., Kim, J. H., Lim, J. H., Park, C. K., Oh, I. J., & Kim, Y. C. (2026). A Noncanonical MET Exon 14 Splice‐Site Variant in Pulmonary Sarcomatoid Carcinoma With Response to Capmatinib. Thoracic Cancer, 17(15). https://doi.org/10.1111/1759-7714.70371
Vancouver
Oh HJ, Choi YD, Choi YL, Park HY, Yoon JY, Kim JH, et al. A Noncanonical MET Exon 14 Splice‐Site Variant in Pulmonary Sarcomatoid Carcinoma With Response to Capmatinib. Thoracic Cancer. 2026;17(15). doi:10.1111/1759-7714.70371
BibTeX
@article{Oh2026,
author = {Oh, Hyung-Joo and Choi, Yoo-Duk and Choi, Yoon-La and Park, Ha-Young and Yoon, Joon-Young and Kim, Jang-Hyeon and Lim, Jung-Hwan and Park, Cheol-Kyu and Oh, In-Jae and Kim, Young-Chul},
title = {A Noncanonical MET Exon 14 Splice‐Site Variant in Pulmonary Sarcomatoid Carcinoma With Response to Capmatinib},
journal = {Thoracic Cancer},
year = {2026},
volume = {17},
number = {15},
doi = {10.1111/1759-7714.70371}
}
EUVIMED